[go: up one dir, main page]

WO1999007324A3 - Conjugates targeted to the interleukin-2 receptor - Google Patents

Conjugates targeted to the interleukin-2 receptor Download PDF

Info

Publication number
WO1999007324A3
WO1999007324A3 PCT/US1998/016290 US9816290W WO9907324A3 WO 1999007324 A3 WO1999007324 A3 WO 1999007324A3 US 9816290 W US9816290 W US 9816290W WO 9907324 A3 WO9907324 A3 WO 9907324A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
interleukin
composition
chemical agent
water soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/016290
Other languages
French (fr)
Other versions
WO1999007324A2 (en
Inventor
Ramesh K Prakash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Laboratories UT Inc
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Priority to CA002299368A priority Critical patent/CA2299368A1/en
Priority to EP98939226A priority patent/EP1011705A4/en
Priority to AU87698/98A priority patent/AU8769898A/en
Priority to JP2000506921A priority patent/JP2003516305A/en
Publication of WO1999007324A2 publication Critical patent/WO1999007324A2/en
Publication of WO1999007324A3 publication Critical patent/WO1999007324A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition for intracellular delivery of a chemical agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chemical agent and at least two copies of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a water soluble polymer. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the composition. The composition also optionally includes a spacer for coupling the chemical agent and the ligand to the polymer. Chemical agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred water soluble polymer is polyalkylene oxide, such as polyethylene glycol and polyethylene oxide, and activated derivatives thereof. The composition can further comprise a carrier such as another water soluble polymer, liposome, or particulate. Methods of using these compositions for delivering a chemical agent in vivo or in vitro are also disclosed.
PCT/US1998/016290 1997-08-05 1998-08-05 Conjugates targeted to the interleukin-2 receptor Ceased WO1999007324A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002299368A CA2299368A1 (en) 1997-08-05 1998-08-05 Conjugates targeted to the interleukin-2 receptor
EP98939226A EP1011705A4 (en) 1997-08-05 1998-08-05 Conjugates targeted to the interleukin-2 receptor
AU87698/98A AU8769898A (en) 1997-08-05 1998-08-05 Conjugates targeted to the interleukin-2 receptor
JP2000506921A JP2003516305A (en) 1997-08-05 1998-08-05 Conjugates targeted to interleukin-2 receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91404297A 1997-08-05 1997-08-05
US08/914,042 1997-08-05

Publications (2)

Publication Number Publication Date
WO1999007324A2 WO1999007324A2 (en) 1999-02-18
WO1999007324A3 true WO1999007324A3 (en) 1999-04-15

Family

ID=25433849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016290 Ceased WO1999007324A2 (en) 1997-08-05 1998-08-05 Conjugates targeted to the interleukin-2 receptor

Country Status (5)

Country Link
EP (1) EP1011705A4 (en)
JP (1) JP2003516305A (en)
AU (1) AU8769898A (en)
CA (1) CA2299368A1 (en)
WO (1) WO1999007324A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
JP2003530299A (en) * 1999-03-08 2003-10-14 ゲルハルト グラウプナー， Methods and compositions for targeted drug delivery
EP1255568A2 (en) * 2000-02-18 2002-11-13 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5059413A (en) * 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
US5149528A (en) * 1987-04-10 1992-09-22 Zymogenetics, Inc. Cytotoxic protein from Trichosanthes kirilowii
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970705404A (en) * 1994-09-13 1997-10-09 찰스 디.에버트 INTRACELLULAR DELIVERY OF CHEMICAL AGENTS TO A SPECIFIC CELL TYPE
ZA972087B (en) * 1996-03-15 1997-10-24 Theratech Inc Targeting macromolecular produgs to T lymphocytes.
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5149528A (en) * 1987-04-10 1992-09-22 Zymogenetics, Inc. Cytotoxic protein from Trichosanthes kirilowii
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5059413A (en) * 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PASTAN I. et al., "Recombinant Toxins for Cancer Treatment", SCIENCE, 22 November 1991, Vol. 254, pages 1173-1177. *
See also references of EP1011705A4 *

Also Published As

Publication number Publication date
WO1999007324A2 (en) 1999-02-18
EP1011705A4 (en) 2000-09-20
JP2003516305A (en) 2003-05-13
EP1011705A2 (en) 2000-06-28
CA2299368A1 (en) 1999-02-18
AU8769898A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
WO2000007543A3 (en) Conjugates targeted to the interleukin-2 receptors
WO2002100336A3 (en) Tissue-specific endothelial membrane proteins
WO1997032572A3 (en) Materials and methods for enhancing cellular internalization
EP0974344A3 (en) Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
IL112372A (en) Non-viral vector for the delivery of genetic information to cells
EP1093819A3 (en) Compounds and compositions for delivering active agents
TR199902731T2 (en) Chemical compounds.
CA2345138A1 (en) Polymer conjugates of interferon beta-1a and their uses
AU3876695A (en) Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
HUP0301102A3 (en) Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
CA2337680A1 (en) Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier
IL143356A0 (en) An oral formulation for gastrointestinal drug delivery
Cho et al. Folate receptor-mediated intracellular delivery of recombinant caspase-3 for inducing apoptosis
WO2001035932A3 (en) Sustained drug delivery from structural matrices
WO2000054730A3 (en) Compositions preparations and uses of human papillomavirus l1 protein
AU2002225878A1 (en) Receptor antagonist-lipid conjugates and delivery vehicles containing same
AU1265097A (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
AU2001276831A1 (en) Delivery vehicle composition and methods for delivering antigens and other drugs
WO2001004334A3 (en) Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 coxsacki adenovirus receptor (car)
CA2423983A1 (en) An immunogenic iscom complex comprising an enzymatically active a1 subunit of the cholera toxin or e. coli heat labile enterotoxin fused to a dimer of the d region of protein a
MX9701860A (en) Intracellular delivery of chemical agents to a specific cell type.
Burtles et al. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) New Drug Development Office
WO1999007324A3 (en) Conjugates targeted to the interleukin-2 receptor
HK1047884A1 (en) Biologically active materials
BR9711081A (en) Targeting of macromolecular prodrugs to t lymphocytes.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2299368

Country of ref document: CA

Ref country code: CA

Ref document number: 2299368

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 87698/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998939226

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998939226

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998939226

Country of ref document: EP